Trastuzumab deruxtecan (Enhertu®)
HSE100061
25049
Trastuzumab deruxtecan
Enhertu®
AstraZeneca
01/08/2025
12/12/2022
Proposal from Applicant Under Review
30/01/2026
Awaiting Proposal from Applicant
15/01/2026
Applicant Meeting Held with CPU
15/01/2026
Full Health Technology Assessment Commissioned by HSE
01/10/2025
Rapid Review Completed
03/09/2025
Rapid Review Commissioned
06/08/2025
Pricing and Reimbursement Application Complete
01/08/2025